Redx Pharma (LSE:REDX) COGS-to-Revenue : 0.00 (As of Sep. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Redx Pharma COGS-to-Revenue?

Redx Pharma's Cost of Goods Sold for the six months ended in Sep. 2023 was £0.00 Mil. Its Revenue for the six months ended in Sep. 2023 was £1.89 Mil.

Redx Pharma's COGS to Revenue for the six months ended in Sep. 2023 was 0.00.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Redx Pharma's Gross Margin % for the six months ended in Sep. 2023 was N/A%.

Redx Pharma COGS-to-Revenue Historical Data

The historical data trend for Redx Pharma's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Redx Pharma COGS-to-Revenue Chart

Redx Pharma Annual Data

Trend

Sep14

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

COGS-to-Revenue

Get a 7-Day Free Trial

0.11

Redx Pharma Semi-Annual Data
	Mar14	Sep14	Mar15	Sep15	Mar16	Sep16	Mar17	Sep17	Mar18	Sep18	Mar19	Sep19	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23
COGS-to-Revenue	Get a 7-Day Free Trial															-	-	-	-	-

Redx Pharma COGS-to-Revenue Calculation

Redx Pharma's COGS to Revenue for the fiscal year that ended in Sep. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	0	/	4.202
	=	0.00

Redx Pharma's COGS to Revenue for the quarter that ended in Sep. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	0	/	1.891
	=	0.00

Redx Pharma (LSE:REDX) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Redx Pharma's Gross Margin % for the six months ended in Sep. 2023 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	0 / 1.891
	=	N/A %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Redx Pharma COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Redx Pharma's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Redx Pharma (LSE:REDX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Redx Pharma PLC (LSE:REDX) » Definitions » COGS-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

Block 33, Mereside, Alderley Park, Macclesfield, GBR, SK10 4TG

Website

https://www.redxpharma.com

Redx Pharma PLC is a United Kingdom-based biotechnology company focused on the development of novel precision medicines that have the potential to transform treatment in oncology and fibrotic diseases. Its product pipeline under development includes Porcupine Inhibitor, ROCK2 Selective Inhibitor, GI-targeted ROCK inhibitor, Pan-RAF Inhibitor, and others. The firm operates geographically in UK and Ireland. Revenue is generated from; Scientific programmes and research collaboration, Research collaboration and Research and preclinical development services. Redx is a clinical-stage biotechnology company focused on the discovery & development of novel, small-molecule, targeted medicines for the treatment of cancer and fibrotic disease and the emerging area of cancer-associated fibrosis.

Redx Pharma (LSE:REDX) Headlines

No Headlines